Alprostadil

DRUG13 trials

Sponsors

Fidia Farmaceutici S.p.A., City of Hope Medical Center, UCB BIOSCIENCES GmbH, Biopeutics Co., Ltd, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Conditions

Children AKI PatientsCoronary Slow Flow PhenomenonCritical Limb IschemiaDiabetesEnd Stage Cardiac FailureErectile DysfunctionExtracorporeal Membrane OxygenationHFrEF - Heart Failure With Reduced Ejection Fraction

Phase 1

A Phase I/II safety and efficacy study of Vibrio alginolyticus collagenase in patients with Peyronie’s Disease A Phase I single ascending dose with a Phase II expansion, safety, tolerability, efficacy, pharmacokinetics and immunogenicity study

RecruitingCTIS2023-509621-45-00

Fidia Farmaceutici S.p.A.Peyronie’s Disease

Start: 2025-04-22Target: 100Updated: 2025-04-30

Phase 2

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

CompletedNCT02228850

NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)Raynaud's Phenomenon Secondary to Systemic Sclerosis

Start: 2014-11-30End: 2015-12-31Updated: 2016-03-22

PGE1 as Additive Anticoagulant in ECMO-Therapy

TerminatedNCT02895373

Thomas StaudingerExtracorporeal Membrane Oxygenation, Respiratory Distress Syndrome, Adult

Start: 2016-07-31End: 2021-07-31Updated: 2022-02-09

Phase 3

ED Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer

TerminatedNCT00544076

City of Hope Medical CenterMale Erectile Disorder, Prostate Cancer, Stage II Prostate Cancer +1

Start: 2006-01-31End: 2012-04-30Updated: 2019-01-02

ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure

Not yet recruitingNCT00610051

Biopeutics Co., LtdEnd Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction, NYHF Class III-IV

Start: 2026-10-31End: 2030-12-31Target: 600Updated: 2025-12-15

Phase 4

Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV

CompletedNCT00596752

UCB BIOSCIENCES GmbHPeripheral Arterial Occlusive Disease

Start: 2004-03-31End: 2013-07-31Updated: 2018-04-04

Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction

WithdrawnNCT01776320

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sErectile Dysfunction

Start: 2013-12-31End: 2015-12-31Updated: 2014-03-04

Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke

Not yet recruitingNCT03252626

The First Hospital of Jilin UniversityStroke

Start: 2024-04-18End: 2025-06-30Target: 950Updated: 2024-04-01

Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI

RenJi HospitalST Segment Elevation Myocardial Infarction

Start: 2017-09-01End: 2019-06-30Target: 600Updated: 2017-08-17

Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP

CompletedNCT03296670

RenJi HospitalCoronary Slow Flow Phenomenon, ST Segment Elevation Myocardial Infarction

Start: 2015-08-01End: 2017-08-31Updated: 2020-03-12

The Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury

Shengjing HospitalChildren AKI Patients

Start: 2019-08-01End: 2021-12-31Target: 300Updated: 2019-03-27

Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Critical Limb Ischemia.

Assiut UniversityCritical Limb Ischemia

Start: 2020-04-01End: 2021-10-01Target: 30Updated: 2020-03-20

Unknown Phase

Blood Flow Change After Free Flap Surgery in Diabetic Patients

CompletedNCT03027219

Asan Medical CenterDiabetes

Start: 2017-01-31End: 2018-11-29Updated: 2018-11-30

Related Papers

Add-On Prostaglandin E <sub>1</sub> in Venovenous Extracorporeal Membrane Oxygenation: A Randomized, Double-Blind, Placebo-controlled Pilot Trial

American Journal of Respiratory and Critical Care Medicine2022-04-1514 citations

Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.

2018-04-2516 citations